{
  "id": 20241389,
  "title": "Tirzepatide Cuts BMI in Adolescents With Obesity in Phase III Trial",
  "url": "https://urgent.news/2026/11/15/tirzepatide-cuts-bmi-in-adolescents-with-obesity-in-phase-iii-trial",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-15T23:00:00.000Z",
  "source": {
    "name": "MedPage Today",
    "slug": "medpage-today",
    "url": "https://www.medpagetoday.com/meetingcoverage/obesityweek/123891"
  },
  "original_language": "en",
  "account": null,
  "summary": "(MedPage Today) -- NATIONAL HARBOR, Md. -- Tirzepatide (Zepbound) yielded substantial reductions in BMI among adolescents with obesity or overweight with obesity-related complications, the phase III SURMOUNT-ADOLESCENTS trial showed. At week...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}